122 related articles for article (PubMed ID: 29329051)
1. Non-genetic engineering of cytotoxic T cells to target IL-4 receptor enhances tumor homing and therapeutic efficacy against melanoma.
Gunassekaran GR; Hong CM; Vadevoo SMP; Chi L; Guruprasath P; Ahn BC; Kim HJ; Kang TH; Lee B
Biomaterials; 2018 Mar; 159():161-173. PubMed ID: 29329051
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal cytotoxic T-cell immunotherapy for metastatic leptomeningeal melanoma.
Clemons-Miller AR; Chatta GS; Hutchins L; Angtuaco EJ; Ravaggi A; Santin AD; Cannon MJ
Clin Cancer Res; 2001 Mar; 7(3 Suppl):917s-924s. PubMed ID: 11300492
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic T lymphocytes generated by short-term in vitro TCR stimulation in the presence of IL-4 are therapeutically effective against B16 melanoma.
Chang ML; Chen YT; Su YC; Kung JT
J Biomed Sci; 2003; 10(6 Pt 1):644-50. PubMed ID: 14576467
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth.
Guruprasath P; Kim J; Gunassekaran GR; Chi L; Kim S; Park RW; Kim SH; Baek MC; Bae SM; Kim SY; Kim DK; Park IK; Kim WJ; Lee B
Biomaterials; 2017 Oct; 142():101-111. PubMed ID: 28732245
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells.
Goding SR; Yu S; Bailey LM; Lotze MT; Basse PH
Clin Immunol; 2017 Apr; 177():76-86. PubMed ID: 27377534
[TBL] [Abstract][Full Text] [Related]
6. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
7. Effector cells derived from naive T cells used in tumor immunotherapy of mice bearing B16 melanoma.
Wen M; Xu W; Ren L; Gao F; Cui N; Wen J; Li X; Lin L; Ma Z; Chen B; Cai J
Chin Med J (Engl); 2014; 127(7):1328-33. PubMed ID: 24709189
[TBL] [Abstract][Full Text] [Related]
8. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cytotoxic T lymphocyte therapy triggers a counter-regulatory immunosuppressive mechanism via recruitment of myeloid-derived suppressor cells.
Hosoi A; Matsushita H; Shimizu K; Fujii S; Ueha S; Abe J; Kurachi M; Maekawa R; Matsushima K; Kakimi K
Int J Cancer; 2014 Apr; 134(8):1810-22. PubMed ID: 24150772
[TBL] [Abstract][Full Text] [Related]
10. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
Sun L; Guo H; Jiang R; Lu L; Liu T; He X
Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
[TBL] [Abstract][Full Text] [Related]
11. Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells.
Chi L; Na MH; Jung HK; Vadevoo SM; Kim CW; Padmanaban G; Park TI; Park JY; Hwang I; Park KU; Liang F; Lu M; Park J; Kim IS; Lee BH
J Control Release; 2015 Jul; 209():327-36. PubMed ID: 25979323
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cytotoxic T lymphocytes recruitment targeting tumor vasculatures by endoglin aptamer and IP-10 plasmid presenting liposome-based nanocarriers.
Yang X; Zhao J; Duan S; Hou X; Li X; Hu Z; Tang Z; Mo F; Lu X
Theranostics; 2019; 9(14):4066-4083. PubMed ID: 31281532
[No Abstract] [Full Text] [Related]
13. Tracking in vivo migration and distribution of antigen-specific cytotoxic T lymphocytes by 5,6-carboxyfluorescein diacetate succinimidyl ester staining during cancer immunotherapy.
Xu WL; Li SL; Wen M; Wen JY; Han J; Zhang HZ; Gao F; Cai JH
Chin Med J (Engl); 2013 Aug; 126(16):3019-25. PubMed ID: 23981604
[TBL] [Abstract][Full Text] [Related]
14. Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8
Hasan AN; Selvakumar A; Shabrova E; Liu XR; Afridi F; Heller G; Riviere I; Sadelain M; Dupont B; O'Reilly RJ
Clin Exp Immunol; 2016 Nov; 186(2):249-265. PubMed ID: 27227483
[TBL] [Abstract][Full Text] [Related]
15. Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models.
Li A; Wu Y; Linnoila J; Pulli B; Wang C; Zeller M; Ali M; Lewandrowski GK; Li J; Tricot B; Keliher E; Wojtkiewicz GR; Fulci G; Feng X; Tannous BA; Yao Z; Chen JW
Cancer Immunol Immunother; 2016 Dec; 65(12):1545-1554. PubMed ID: 27722909
[TBL] [Abstract][Full Text] [Related]
16. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model.
Oflazoglu E; Elliott M; Takita H; Ferrone S; Henderson RA; Repasky EA
J Transl Med; 2007 Jun; 5():29. PubMed ID: 17592641
[TBL] [Abstract][Full Text] [Related]
17. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
Liu S; Riley J; Rosenberg S; Parkhurst M
J Immunother; 2006; 29(3):284-93. PubMed ID: 16699371
[TBL] [Abstract][Full Text] [Related]
18. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
[TBL] [Abstract][Full Text] [Related]
19. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice.
Sabzevari H; Reisfeld RA
Cancer Res; 1993 Oct; 53(20):4933-7. PubMed ID: 8402683
[TBL] [Abstract][Full Text] [Related]
20. Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells.
Crowley NJ; Vervaert CE; Seigler HF
Cancer Res; 1992 Jan; 52(2):394-9. PubMed ID: 1728411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
